Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) CEO Mac Armstrong sold 3,500 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $114.39, for a total value of $400,365.00. Following the completion of the sale, the chief executive officer directly owned 332,888 shares of the company’s stock, valued at approximately $38,079,058.32. This trade represents a 1.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mac Armstrong also recently made the following trade(s):
- On Tuesday, April 21st, Mac Armstrong sold 3,500 shares of Palomar stock. The stock was sold at an average price of $130.77, for a total value of $457,695.00.
- On Wednesday, April 15th, Mac Armstrong sold 3,197 shares of Palomar stock. The stock was sold at an average price of $129.46, for a total value of $413,883.62.
- On Monday, March 23rd, Mac Armstrong sold 3,500 shares of Palomar stock. The stock was sold at an average price of $120.58, for a total value of $422,030.00.
Palomar Stock Performance
Shares of Palomar stock opened at $113.87 on Friday. The stock has a market cap of $3.02 billion, a PE ratio of 15.86 and a beta of 0.49. The business has a fifty day simple moving average of $120.66 and a 200-day simple moving average of $124.48. The company has a quick ratio of 0.49, a current ratio of 0.49 and a debt-to-equity ratio of 0.31. Palomar Holdings, Inc. has a 12 month low of $107.51 and a 12 month high of $175.85.
Hedge Funds Weigh In On Palomar
Institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. bought a new position in Palomar during the fourth quarter valued at about $32,000. Kestra Advisory Services LLC bought a new position in Palomar during the fourth quarter valued at about $33,000. Rockefeller Capital Management L.P. raised its holdings in Palomar by 81.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company’s stock valued at $40,000 after buying an additional 132 shares in the last quarter. Clearstead Advisors LLC raised its holdings in Palomar by 31.0% during the third quarter. Clearstead Advisors LLC now owns 397 shares of the company’s stock valued at $46,000 after buying an additional 94 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Palomar by 638.3% during the first quarter. Parallel Advisors LLC now owns 443 shares of the company’s stock valued at $53,000 after buying an additional 383 shares in the last quarter. 90.25% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on PLMR. Evercore began coverage on Palomar in a research report on Monday, February 9th. They issued an “outperform” rating and a $150.00 target price for the company. Piper Sandler decreased their target price on Palomar from $151.00 to $132.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Weiss Ratings cut Palomar from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, May 7th. Zacks Research cut Palomar from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 15th. Finally, Wall Street Zen cut Palomar from a “buy” rating to a “hold” rating in a research report on Sunday, March 1st. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $150.25.
Check Out Our Latest Stock Report on Palomar
About Palomar
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Read More
- Five stocks we like better than Palomar
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
- MarketBeat Week in Review – 05/18 – 05/22
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
